There are not any 6 monthly injections for MS, but there is one treatment administered every six months via intravenous (IV) infusion.
OCREVUS for Multiple Sclerosis
OCREVUS is an FDA-approved medication used to treat both relapsing and primary progressive forms of multiple sclerosis (MS). It is administered through intravenous (IV) infusion every six months, not by injection. This treatment targets a specific type of immune cell, CD20-positive B cells, which play a key role in MS.
Key Facts about OCREVUS:
- Administration: Given through intravenous infusion (IV), not an injection.
- Frequency: Administered once every six months.
- Target: It works by targeting CD20-positive B cells, a type of immune cell involved in the disease process.
- Conditions Treated: Approved for relapsing and primary progressive forms of MS.
How OCREVUS Works:
OCREVUS works by reducing the number of B cells that are thought to contribute to the damage caused in MS. This helps to reduce the inflammation and subsequent nerve damage associated with MS.
| Treatment | Method | Frequency | Target | Conditions Treated |
|---|---|---|---|---|
| OCREVUS | IV Infusion | Every six months | CD20-positive B cells | Relapsing and Primary Progressive MS |
It's important to note that while OCREVUS is given every six months, the administration method is an infusion, not an injection. If you have been prescribed this treatment, it is essential to discuss the process, potential side effects, and specific details with your healthcare provider.
